Document is current
Any future updates will be listed below
-
Authors
Leffler, Jarrod M.
Azzopardi, Daniel
Jensen, Peter S.
Croarkin, Paul E.
Cullen, Kathryn R.
Duffy, Anne
Klimes-Dougan, Bonnie
Post, Robert M.
Vande Voort, Jennifer L.
Wagner, Karen Dineen
Wolf, Dwight V.
Galanter, Cathryn A.
- License Information
-
More Information
Article History
Accepted: 25 November 2024
First Online: 9 January 2025
Declarations
:
: Dr. Croarkin receives research support from the National Institutes of Health (NIH). Dr. Croarkin has received research grant support from Pfizer, Inc. and in kind support from Assurex (supplies and genotyping), Neuronetics, Inc. (equipment), and MagVenture, Inc. (equipment). He was the primary investigator for a multicenter study funded by Neuronetics, Inc. and a site primary investigator for a study funded by NeoSync, Inc. Dr. Croarkin served as an advisory board member for Engrail Therapeutics, Sunovion, Procter & Gamble Company, and Myriad Neuroscience. Dr. Cullen receives research support from the NIH, the National Endowment for the Arts, Minnesota State Arts Board, and the University of Minnesota. She serves as a consultant to the Pediatric Advisory Committee of the Food and Drug Association. Dr. Duffy holds grants from the Canadian Institutes for Health Research. Dr. Post has spoken for Sunovion until recently. Dr. Galanter is on the scientific steering committee of the REACH Institute and receives honorarium from American Psychiatric Publishing. Dr. Vande Voort has received in kind support from Assurex (supplies and genotyping only).
: We confirm that our research received approval from the Institutional Review Board (IRB) to be conducted. Participants provided informed consent to participate in the study and to have the results published.
